@adaclipsadmin's HCG claims need some context

What did @adaclipsadmin actually say?

The creator, presenting as a physician, made several specific claims about human chorionic gonadotropin (HCG): that subcutaneous injection has a half-life of 16-20 hours versus only six hours intramuscularly, that HCG is an emerging treatment for anabolic steroid-induced hypogonadism (ASIH), that long-term HCG monotherapy causes testicular desensitization, and that HCG alone as a testosterone replacement strategy is not viable for most men. He also said it should only be used in men who need to restore fertility.

To his credit, he was transparent about the limits of existing data. His exact words: "We have no data." That kind of epistemic honesty is rarer than it should be on TikTok, especially in the TRT content space. He is not selling a miracle. He is describing clinical reality, messily but mostly accurately.

Does the science back this up?

The pharmacokinetics claim is the most specific and the most checkable. It is also where things get complicated. The evidence is thinner than the creator implies.

A widely cited pharmacokinetic study by Stenman et al. (1997, Human Reproduction) found HCG half-life varies significantly by formulation and individual, with the beta subunit showing a terminal half-life of roughly 24-36 hours regardless of route in most subjects. The idea that IM produces a dramatically shorter half-life than subcutaneous is not well-supported by controlled human data. Some practitioners cite shorter IM absorption windows based on clinical observation, but this is not the same as peer-reviewed pharmacokinetic confirmation.

On ASIH, the science is more supportive. Coward et al. (2013, Journal of Urology) documented the scale of ASIH in men presenting to urology clinics, and the use of HCG to restore hypothalamic-pituitary-gonadal axis function has biological plausibility given its LH-mimicking mechanism. Boregowda et al. (2019, European Journal of Endocrinology) reviewed recovery of gonadal function after anabolic steroid cessation and found HCG-based protocols can accelerate LH receptor stimulation, though recovery timelines vary widely.

What did they get wrong (or right)?

The half-life comparison is the shakiest claim here. Saying IM absorption is "only six hours" versus subcutaneous "16 to 20 hours" presents a specific numerical contrast as if it is settled pharmacology. It is not. The creator should have flagged this as clinical observation rather than established data.

What he got right: the desensitization concern is real and documented. Chronic HCG administration leads to Leydig cell desensitization via LH receptor downregulation, a mechanism described in animal models by Andersen et al. (1999, Biology of Reproduction) and clinically observed in fertility medicine. His acknowledgment that "most men say at a certain point my testicles start to shrink despite increased doses" reflects a genuine clinical phenomenon, not fearmongering.

He also correctly identified that HCG monotherapy for TRT is not a standard or practical approach. Bhasin et al. (2010, Journal of Clinical Endocrinology and Metabolism) established testosterone as the reference standard for hypogonadism treatment. HCG monotherapy does not reliably produce stable serum testosterone levels in all men, and most clinical guidelines do not recommend it as primary TRT.

• Half-life numbers presented with more precision than evidence supports
• Desensitization risk: accurate and clinically relevant
• HCG monotherapy limitations: accurate
• ASIH as an emerging indication: supported, though still under-researched

What should you actually know?

HCG is not a simple drug and this video, despite its rough edges, captures that complexity better than most TRT content does. Here is what actually matters if you or a patient are considering it.

HCG is used in TRT primarily to preserve testicular volume and maintain intratesticular testosterone during exogenous testosterone therapy. Coviello et al. (2005, Journal of Clinical Endocrinology and Metabolism) showed that low-dose HCG (125-500 IU every other day) maintained intratesticular testosterone in testosterone-treated men. This is the most evidence-backed use case.

For ASIH recovery, HCG is used as part of structured post-cycle or recovery protocols, but the evidence base for specific protocols is largely observational. There is no large randomized controlled trial establishing an optimal ASIH recovery regimen.

If you are on a telehealth platform and a provider recommends HCG, the relevant questions are: what is the clinical goal, how will response be monitored, and what is the plan if desensitization occurs? Those are not questions most TikTok videos answer. This one at least raises them.

Bottom line

This is a clinician sharing real clinical experience with a drug that does not have a clean evidence base. The instinct to personalize dosing and route, and to be honest about what data exists, is appropriate. The specific pharmacokinetic numbers deserve more skepticism than they got. Anyone making medical decisions based on a 60-second TikTok, however credentialed the creator, is working with incomplete information.